PT  - JOURNAL ARTICLE
AU  - OHASHI, YASUKATA
AU  - YATABE, MEGUMI
AU  - NIIJIMA, DAISUKE
AU  - TANI, KENTARO
AU  - OGAWA, CHIAKI
AU  - YACHI, YUTAKA
AU  - KAGOO, TOSHIYA
AU  - BOKU, SAIGEN
AU  - UENO, HIRONORI
AU  - YANO, TAKAHIRO
AU  - HIGAI, KOJI
AU  - YOKOYAMA, AKIHIRO
TI  - Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
AID  - 10.21873/invivo.12108
DP  - 2020 Sep 01
TA  - In Vivo
PG  - 2821--2828
VI  - 34
IP  - 5
4099  - http://iv.iiarjournals.org/content/34/5/2821.short
4100  - http://iv.iiarjournals.org/content/34/5/2821.full
SO  - In Vivo2020 Sep 01; 34
AB  - Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We retrospectively evaluated 17 consecutive patients treated with IRd (10 patients on ixazomib dose-escalation strategy (2.3 mg starting dose); seven patients on standard dose). Results: The incidence of grade 3 or more haematological and grade 2 or more non-haematological adverse events was lower in the dose-escalation group than in the standard-dose group, and only that of diarrhoea was significantly lower. The median time to treatment interruption was significantly longer in the dose-escalation group than in the standard-dose group. There was no significant difference in the overall response rate (20% vs. 43%) and disease control rate (70% vs. 86%). Conclusion: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity.